Business
Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
– IMU-856 is an Orally Available, Systemically Acting, Highly Selective and Potent Small Molecule Modulator of SIRT6 – – Targets Regeneration of Bowel
About this update from Immunic, Inc.
[{"type":"text","content":"– IMU-856 is an Orally Available, Systemically Acting, Highly Selective and Potent Small Molecule Modulator of SIRT6 –\n– Targets Regeneration of Bowel Epithelium and Restoration of Intestinal Barrier Function –\n– Builds on Recently Released Phase 1b Data Showing Beneficial Effects in Celiac Disease Histology, Disease Symptoms, Biomarkers and Nutrient Absorption –\n– Virtual ePoster to be Presented Today, May 6, 2023, During 9:30 am - 4:00 pm CT Poster Session –\nNEW YORK, May 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of clinical and preclinical data for IMU-856. Included in this presentation are new data on IMU-856's mode of action as a potent modulator of SIRT6 (Sirtuin 6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.\nIMU-856 is a highly selective and potent small molecule which has been shown to modulate, stabilize and enhance expression of the SIRT6 protein, in particular, in the gastrointestinal tract. In the small intestine, SIRT6 expression is highest among absorptive enterocytes which are responsible for nutrient uptake, mucus-producing goblet cells which protect the wall's lining, and Paneth cells which support, protect and stimulate local regenerative stem cells. Modulation of these cell types by IMU-856 appears to direct local stem cells to divide and then differentiate into 'new' intestinal epithelial cells, thereby stimulating the natural physiologic process of renewal of the gut wall lining.\nIn both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining. In a preclinical DSS (dextran sodium sulfate) colitis model, IMU-856 treatment protected and also improved regeneration of the gut lining, as measured by normalization of crypt architecture. IMU-856 treatment also induced a dose-dependent tightening of the intestinal barrier, as measured by TEER (transepithelial electrical resistance) assay. Gene expression experi...